Skip to main content
. 2022 May 4;17(5):e0266980. doi: 10.1371/journal.pone.0266980

Fig 2. Co-expression of GPC3-targeted CAR with exogenous GOT2 in BOXR1030 T cells.

Fig 2

(A) Depiction of expression construct and domains for the GPC3 CAR and BOXR1030 used in studies. (B) Representative surface expression of the anti-GPC3 scFv following transduction, measured on day 9 by flow cytometry from a single donor. (C) Summarized CAR expression by flow cytometry for n = 5 healthy donors. (D) mRNA copy number of endogenous and exogenous (codon optimized) GOT2 measured by qPCR (n = 3 donors). (E) The frequency of CD45RA+ CD27+, CD45RA+ CD27-, CD45RA- CD27+, and CD45RA- CD27- T cells in the indicated subsets at baseline (n = 11 healthy donors; no stimulation). P-values were determined by paired t-test. Data represented as mean+/- standard deviation (SD).